Terms: = Sarcomas AND PIM1, PIM, 5292, ENSG00000137193, P11309 AND Prognosis
5 results:
1. Design and synthesis of a novel mitochondria-targeted osteosarcoma theranostic agent based on a pim1 kinase inhibitor.
Yi X; Cao Z; Yuan Y; Li W; Cui X; Chen Z; Hu X; Yu A
J Control Release; 2021 Apr; 332():434-447. PubMed ID: 33662457
[TBL] [Abstract] [Full Text] [Related]
2. miR-486 inhibited osteosarcoma cells invasion and epithelial-mesenchymal transition by targeting pim1.
Liu Y; Zhang J; Xing C; Wei S; Guo N; Wang Y
Cancer Biomark; 2018; 23(2):269-277. PubMed ID: 30103304
[TBL] [Abstract] [Full Text] [Related]
3. Expression and function of pim kinases in osteosarcoma.
Mou S; Wang G; Ding D; Yu D; Pei Y; Teng S; Fu Q
Int J Oncol; 2016 Nov; 49(5):2116-2126. PubMed ID: 27826617
[TBL] [Abstract] [Full Text] [Related]
4. Clinical and biological significance of pim1 kinase in osteosarcoma.
Liao Y; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
J Orthop Res; 2016 Jul; 34(7):1185-94. PubMed ID: 26687194
[TBL] [Abstract] [Full Text] [Related]
5. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.
Lu XY; Lu Y; Zhao YJ; Jaeweon K; Kang J; Xiao-Nan L; Ge G; Meyer R; Perlaky L; Hicks J; Chintagumpala M; Cai WW; Ladanyi M; Gorlick R; Lau CC; Pati D; Sheldon M; Rao PH
Mol Cancer Res; 2008 Jun; 6(6):937-46. PubMed ID: 18567798
[TBL] [Abstract] [Full Text] [Related]